Search Results - "Propper D"

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.

Authors: Levitt, N. C. Propper, D. J. Madhusudan, S. et al.

Source: British Journal of Cancer. 7/11/2005, Vol. 93 Issue 1, p60-69. 10p.

Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha.

Authors: Braybrooke, J P Propper, D J O’Byrne, K J et al.

Source: British Journal of Cancer. 7/15/2000, Vol. 83 Issue 2, p219. 6p.

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.

Authors: Propper, D J Braybrooke, J P Levitt, N C et al.

Source: British Journal of Cancer. 6/1/2000, Vol. 82 Issue 11, p1759. 5p.

Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer.

Authors: Propper, D J Levitt, N C O’Byrne, K et al.

Source: British Journal of Cancer. 6/1/2000, Vol. 82 Issue 11, p1776. 7p.

Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma.

Authors: Propper, D. Davidenko, I. Bridgewater, J. et al.

Source: Annals of Oncology. Jul2014, Vol. 25 Issue 7, p1384-1390. 7p.

Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion.

Authors: Woo, J. Propper, D. J. Macleod, A. M. et al.

Source: Clinical & Experimental Immunology. Dec1990, Vol. 82 Issue 3, p462-468. 7p.

A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer.

Authors: Madhusudan, S. Protheroe, A. Propper, D. et al.

Source: British Journal of Cancer. 10/20/2003, Vol. 89 Issue 8, p1418-1422. 5p.

Incidence of IgA nephropathy in UK.

Authors: Propper, D J Power, D A Simpson, J G et al.

Source: Lancet. 1/23/1988, Vol. 1 Issue 8578, p190-190. 1p.

A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study).

Authors: Stebbing, J Harrison, M Glynne-Jones, R et al.

Source: British Journal of Cancer. 2/26/2008, Vol. 98 Issue 4, p716-719. 4p. 3 Charts.

Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane.

Authors: Anderson, H Yap, J T Wells, P et al.

Source: British Journal of Cancer. 7/21/2003, Vol. 89 Issue 2, p262-267. 6p.

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma.

Authors: Corrie, P. G. Qian, W. Basu, B. et al.

Source: British Journal of Cancer. Jun2020, Vol. 122 Issue 12, p1760-1768. 9p. 3 Charts, 3 Graphs.

Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer

Authors: Maraveyas, A. Waters, J. Roy, R. et al.

Source: European Journal of Cancer. Jun2012, Vol. 48 Issue 9, p1283-1292. 10p.

6577 POSTER Investigating Potential Biomarkers for Survival With Erlotinib in Patients With Advanced Pancreatic Cancer – Results of the Phase II B021129 Study

Authors: Ducreux, M. Davidenko, I. Bridgewater, J. et al.

Source: European Journal of Cancer. Sep2011 Supplement 1, Vol. 47, pS464-S464. 1p.

OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)

Authors: Maraveyas, A. Waters, J. Roy, R. et al.

Source: Thrombosis Research. Apr2010 Supplement 2, Vol. 125, pS161-S161. 1p.

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation.

Authors: Flanders L Savy T Ficial M et al.

Source: British journal of cancer [Br J Cancer] 2026 Jul; Vol. 135 (2), pp. 232-239. Date of Electronic Publication: 2026 Apr 18.

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE

Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.

Authors: Iveson T Saunders MP Kelly C et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2026 Mar; Vol. 44 (7), pp. 534-539. Date of Electronic Publication: 2026 Jan 09.

Publication Type: Journal Article

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE; In Process

Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2.

Authors: Kocher HM Sasieni P Corrie P et al.

Corporate Authors: Kocher HM Sasieni P Corrie P et al.

Source: BMC cancer [BMC Cancer] 2025 Jan 20; Vol. 25 (1), pp. 106. Date of Electronic Publication: 2025 Jan 20.

Publication Type: Journal Article; Clinical Trial Protocol

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer.

Authors: Jameson GS LeGrand SD Gordon MS et al.

Source: Redox biology [Redox Biol] 2025 Dec; Vol. 88, pp. 103895. Date of Electronic Publication: 2025 Oct 25.

Publication Type: Journal Article; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

Journal Info: Publisher: Elsevier, B.V Country of Publication: Netherlands NLM ID: 101605639 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2317 (Electronic) Linking ISSN: 22132317 NLM ISO Abbreviation: Redox Biol Subsets: MEDLINE

Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical Trial.

Authors: Gögenur M Rosen AW Iveson T et al.

Source: JAMA surgery [JAMA Surg] 2024 Aug 01; Vol. 159 (8), pp. 865-871.

Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Equivalence Trial

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101589553 Publication Model: Print Cited Medium: Internet ISSN: 2168-6262 (Electronic) Linking ISSN: 21686254 NLM ISO Abbreviation: JAMA Surg Subsets: MEDLINE

A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer.

Authors: Antal CE Oh TG Aigner S et al.

Source: Nature communications [Nat Commun] 2023 Sep 06; Vol. 14 (1), pp. 5195. Date of Electronic Publication: 2023 Sep 06.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE